Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-Course Radiotherapy + CAPOX + Serplulimab + Bevacizumab for MSS-Type LARC
NCT07347951Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of Wenzhou Medical University
- Start
- Dec 2025
- Primary completion
- Dec 2027
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of serplulimab, bevacizumab in locally advanced rectal cancer (LARC), sponsored by The First Affiliated Hospital of Wenzhou Medical University. Started Dec 2025; status: recruiting.
02
Drugs
serplulimabbevacizumab
03
Conditions
locally advanced rectal cancer (LARC)
Beyond the preview
Go deeper on NCT07347951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07347951.